GeneNews Limited, an emerging molecular diagnostic company based in Toronto, Canada, has reportedly completed a $2.5-million “Rights Offering” to holders of its common shares by issuing 23,224,529 shares at 11 cents per share. According to the company, its patented core platform technology, the Sentinel Principle®, can detect a range of diseases or medical conditions, such as cancer, arthritis, cardiovascular disease, and neurological disorders, from a simple blood sample. The company plans to apply the technology to expand the commercialization of its lead product ColonSentry, which can assess colorectal cancer risk without a colonoscopy and was recently launched in New York and New Jersey. See GeneNews Press Release, June 12, 2012.